Nouveau patient au Centre du Cancer et d'hématologie ? Appelez le 02 764 12 00

Hématologie-oncologie pédiatrique

 

 

- Aplasies Médullaires

- HIV

- Leucémie Myéloïde Aiguë (LMA)

- Lymphome d’Hodgkin (LH)

- Lymphome Non-Hodgkinien (LNH)

- Nephroblastome

- Neuroblastome

- Neuropsychologie et Logopédie

- Pathologies Rhumatologiques

- Sarcomes des Tissus Mous

- Troubles de l’hémostase

- Tumeurs du Système Nerveux

- Tumeurs Osseuses

- Divers

 

 

Aplasies Médullaires


“Genetic and Immunological Characterization of Acquired Severe Aplastic Anemia (SAA) in Children and Adolescents” EWOG-SAA

Sponsor: University Hospital Freiburg - Germany

Principal Investigator: Prof. A. Van Damme

Contact: H. Waterloos 02/764 23 13

 

“Prospective non-randomized multi-center study for epidemiology and characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML) in childhood” EWOG-MDS 2006

Sponsor: University Hospital Freiburg - Germany
Principal Investigator: Prof. B. Brichard

Contact: H. Waterloos 02/764 23 13

 

Histiocytose de Langerhans


“International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis” LCH IV
Sponsor : St. Anna’s Kinderkrebsforschung – Children’s Cancer Research Institute (CCRI) – Vienna - Austria
Principal Investigator : Prof. A. Van Damme
Contact : H. Waterloos 02/764 23 13

 

HIV


“European Collaborative Study protocol. Follow-up on children born from HIV positive mothers” HIV-ECS
Sponsor : Institute of Child Health – University College London – United Kingdom
Principal Investigator : Prof. B. Brichard
Contact : H. Waterloos 02/764 23 13

 

“Cohort of young adults infected with HIV through vertical or childhood followed in Belgium” HIV-COVERTE
Sponsor : INSERM – Institut National de la Santé et de la Recherche Médicale - France
Principal Investigator : Prof. D. Van Der Linden
Contact : H. Waterloos 02/764 23 13

 

“Transitum : A retrospective study on HIV-infected adolescents after transfert to adult clinic in Belgium”. TRANSITUM
Sponsor : Cliniques Universitaires Saint-Luc - Belgium
Principal Investigator : Prof. D. Van Der Linden
Contact : H. Waterloos 02/764 23 13

 

Leucémie Lymphoblastique Aiguë (LLA)


“Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia” ALL-SCTped-NOR
Sponsor : St. Anna’s Kinderkrebsforschung – Children’s Cancer Research Institute (CCRI) – Vienna - Austria
Principal Investigator : Prof. A. Van Damme
Contact : G. Dufour 02/764 23 76


“A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With High-risk First Relapse B-precursor Acute Lymphoblastic” BiTE Blinatumomab
Sponsor : AMGEN N.V.
Principal Investigator : Prof. A. Van Damme
Contact : M. Vanden Eynden 02/764 23 76

 

“Translational research – observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukemia (ALL)” EORTC 58081
Sponsor : EORTC AISBL
Principal Investigator : Prof. B. Brichard
Contact : H. Waterloos 02/764 23 13

 

“International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia” EORTC 58051
Sponsor : EORTC AISBL
Principal Investigator : Prof. C. Vermylen
Contact : H. Waterloos 02/764 23 13

 

“IntReALL SR 2010 : International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010” EORTC 58111
Sponsor : Charité – Universitätsmedizin Berlin - Germany
Principal Investigator : Prof. A. Van Damme
Contact : H. Waterloos 02/764 23 13


Leucémie Myéloïde Aiguë (LMA)


“NOPHO-DBH AML 2012 : Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years” NOPHO-DBH AML 2012
Sponsor : Västra Götaland Regionen – Vänersborg - Sweden
Principal Investigator : Prof. B. Brichard
Contact : H. Waterloos 02/764 23 13

 

“Pediatric Relapsed AML 2010/01: International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia” AML Relapse

Sponsor : Hannover Medical School, AML-BFM Group - Germany
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76

 

Lymphome d’Hodgkin (LH)


“European Network-Paediatric Hodgkin Lymphoma Group (EuroNet-PHL) – Second International Inter-Group study for Classical Hodgkin Lymphoma in Children and Adolescents” EuroNet-PHL-C2
Sponsor : Justus Liebig University of Giessen - Germany
Principal Investigator : Prof. A. Van Damme
Contact : M. Vanden Eynden 02/764 23 76

 

“European Network-Paediatric Hodgkin Lymphoma Group (EuroNet-PHL) – First International Inter-Group study for Classical Hodgkin Lymphoma in Children and Adolescents” EuroNet-PHL-C1
Sponsor : Universitätsklinik und Poliklinik für Kinder- und Jugendmedizin (UKH) – Halle/Wittenberg - Germany
Principal Investigator : Prof. C. Vermylen
Contact : M. Vanden Eynden 02/764 23 76


Lymphome Non-Hodgkinien (LNH)


“Intergroup trial for children or adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab efficacy and safety in High Risk patients” Inter-B-NHL-Ritux
Sponsor : Institut Gustave Roussy - France
Principal Investigator : Prof. B. Brichard
Contact : H. Waterloos 02/764 23 13

 

Nephroblastome


“Nephroblastoma, Wilms disease, Clinical trial SIOP 2001”
Sponsor : SIOP Nephroblastoma Trial and Study Office, Dr de Kraker
Principal Investigator : Prof. B. Brichard
Contact : H. Waterloos 02/764 23 13

 

Neuroblastome


“A phase I/II dose schedule finding study of CH14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma.” LTI Study
Sponsor : St. Anna’s Kinderkrebsforschung – Children’s Cancer Research Institute (CCRI) – Vienna - Austria
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76

 

 “European Low and Intermediate Risk Neuroblastoma study” LINES
Sponsor : FUNDACION PARA LA INVESTIGACION HOSPITAL UNIVERSITARIO LA FE - SPAIN
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76


“High Risk Neuroblastoma Study 1.5 of SIOP-Europe (SIOPEN)” HR-NBL-01
Sponsor : St. Anna’s Kinderkrebsforschung – Children’s Cancer Research Institute (CCRI) – Austria
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76

 

Neuropsychologie et Logopédie


« Développement langagier et leucémie lymphoblastique aiguë » LLA et langage
Sponsor : Université Catholique de Louvain (UCL) - Belgium
Principal Investigator : Sophie Hancisse
Contact : M. Vanden Eynden 02/764 23 76

 

« Etude du développement langagier d’enfants suivis dans le cadre d’une tumeur cérébrale » Tumeurs & Langage
Sponsor : Université Catholique de Louvain (UCL) - Belgium
Principal Investigator : Sophie Hancisse
Contact : M. Vanden Eynden 02/764 23 76

 

« Les effets à long-terme de la chimiothérapie sur le développement et les habiletés neurocognitives des patients suivis dans le cadre d’un sarcome des os ou des tissus mous » Neuropsy Sarcomes
Sponsor : Universitair Ziekenhuis Leuven (UZ Leuven) - Belgium
Principal Investigator : Sophie Hancisse / Prof. A. Van Damme
Contact : M. Vanden Eynden 02/764 23 76

 

Pathologies Rhumatologiques


“ß-SPECIFIC 4 Patients : Study of Pediatric EffiCacy and Safety wIth FIrst-line use of Canakinumab. An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and safety study in patients with Systemic Juvenile Idiopathic Arthritis (SJIA)” CanakiG2306

Sponsor : Novartis Pharma SA
Principal Investigator : Prof. B. Lauwerys
Contact : G. Dufour 02/764 23 76

 

“A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal / dosing frequency reduction and open-label long term treatment epochs” CanakiN2301

Sponsor : Novartis Pharma SA
Principal Investigator : Prof. B. Lauwerys
Contact : G. Dufour 02/764 23 76

 

Sarcomes des Tissus Mous


“European paediatric Soft tissue sarcoma Study Group (EpSSG) – RMS 2005 protocol : study for the treatment of non-metastatic rhabdomyosarcoma” RMS 2005
Sponsor : EpSSG Group
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76


“Open-label, multi-center, randomized, phase II study evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma” BERNIE
Sponsor : Roche SA
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76


“NRSTS 2005 : a protocol for Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas in children, adolescents and young adults” NRSTS 2005
Sponsor : EpSSG Group
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76

 

Troubles de l’hémostase

 

"30-day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosis"  Einstein Jr Phase IIb

Sponsor : Bayer AG
Principal Investigator : Prof. A. Van Damme
Contact : G. Dufour 02/764 23 76

 

“Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism” Einstein Jr Phase III

Sponsor : Bayer AG
Principal Investigator : Prof. A. Van Damme
Contact : G. Dufour 02/764 23 76

 

“A post authorization safety surveillance registry in previously untreated patients with severe hemophilia A in usual care settings” ReFacto
Sponsor : Pfizer
Principal Investigator : Prof. A. Van Damme
Contact : G. Dufour 02/764 23 76

 

“Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%)” BAX 855
Sponsor : BAXALTA S.A.S
Principal Investigator : Prof. A. Van Damme
Contact : M. Vanden Eynden 02/764 23 76

 

“An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B” BIOGEN-Hemophilie B
Sponsor : BIOGEN IDEC Limited, UK
Principal Investigator : Prof. A. Van Damme
Contact : G. Dufour 02/764 23 76

 

“A Single Arm, Open-Label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Paediatric Subjects With Immune Thrombocytopenia (ITP)” AMGEN PTI
Sponsor : AMGEN N.V.
Principal Investigator : Prof. B. Brichard
Contact : G. Dufour 02/764 23 76

Tumeurs du Système Nerveux


“SIOP EPENDYMOMA II : An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma” SIOP EPENDYMOMA II
Sponsor : Centre Léon Bérard – Lyon, France
Principal Investigator : Prof. A. Van Damme
Contact : M. Vanden Eynden 02/764 23 76

 

“Diagnostic re-evaluation and pooled clinical analysis of patients with diagnosis of CNS-PNET” CNS-PNET
Sponsor : University Hospital of Bonn Medical Center, University Hospital of Hamburg Eppendorf, German Cancer Research Center (DKFZ) - Germany
Principal Investigator : Prof. A. Van Damme
Contact : M. Vanden Eynden 02/764 23 76

 

“INTELLANCE 2: ABT 414 alone or ABT 414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group” INTELLANCE 2
Sponsor : AbbVie SA/NV
Principal Investigator : Prof. A. Van Damme
Contact : M. Vanden Eynden 02/764 23 76

 

“Conservative treatment of patients with extensive retinoblastoma” Retino 2010
Sponsor : Cliniques Universitaires Saint-Luc
Principal Investigator : Prof. B. Brichard
Contact : H. Waterloos 02/764 23 13

 

“KRANIOPHARYNGEOM 2007 : A Multicenter Prospective Study of Children and Adolescents with Craniopharyngioma” Kraniopharyngeom 2007
Sponsor : German Society for Pediatric Oncology and Hematology (GPOH) - Germany
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76

 

“An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-risk Biological Profile” PNET 5 MB - LR
Sponsor : University Medical Center Hamburg-Eppendorf - Germany
Principal Investigator : Prof. A. Van Damme
Contact : M. Vanden Eynden 02/764 23 76

 

Tumeurs Osseuses


“EWING 2008” Ewing 2008
Sponsor : Universitätsklinikum Münster - Germany
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76

 

“Euro Ewing 2012 : International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing’s Sarcoma Family of Tumours” Euro-Ewing 2012
Sponsor : University of Birmingham – United Kingdom
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76

 

“rEECur : International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma” rEECur
Sponsor : University of Birmingham – United Kingdom
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76

 

Divers


“A randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients with iron overload” Exjade 2
Sponsor : Novartis Pharma SA
Principal Investigator : Prof. B. Brichard
Contact : G. Dufour 02/764 23 76

 

“Multinational European Trial for Children with the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome” OMS/DES
Sponsor : Institut Curie – Paris - France
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76

 

“A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects with Neutropenia” MK-5592-097 Posaconazole

Sponsor : Merck Sharp & Dohme Corp.
Principal Investigator : Prof. B. Brichard
Contact : M. Vanden Eynden 02/764 23 76

 

“An open-label, randomized, adaptive, two-arm, multicenter trial to evaluate pharmacokinetics and pharmacodynamics of two doses of Oseltamivir (Tamiflu) in the treatment of influenza in immunocompromised children, from 2 weeks to less than 13 years of age, with confirmed influenza infection” TAMIFLU
Sponsor : F. Hoffmann-La Roche Ltd
Principal Investigator : Prof. B. Brichard
Contact : G. Dufour 02/764 23 76

 

“Monitoring of Asparaginase therapy in primary childhood acute leukemia and non-Hodgkin Lymphoma” Asparaginase
Sponsor : Universitair Ziekenhuis Gent (UZ Gent) - Belgium
Principal Investigator : Prof. B. Brichard
Contact : G. Dufour 02/764 23 76

 

Cliniques Universitaires St-Luc, Av Hippocrate, 10 - 1200 Bruxelles - Belgique | Tél: 02/764 11 11 | FAX: 02/764 37 03 | Plan d'accès

2019 Institut Roi Albert II, Cliniques Universitaires St-Luc  -  Crédit photos - © Clin.univ.St-Luc / H. Depasse